HOME >> MEDICINE >> NEWS
Weizmann Institute Prof. Moshe Oren named winner of NIH MERIT Award

Washington, D.C.--Prof. Moshe Oren, a cancer researcher at the Weizmann Institute of Science in Israel, was named a 2003 winner of the highly selective MERIT (Method to Extend Research in Time) Award. The award is granted by the National Institutes of Health (NIH) for "long-term support to investigators with impressive records of scientific achievement in research areas of special importance or promise."

The NIH hopes the MERIT Award will encourage scientists to "take greater risks, be more adventurous in the lines of inquiry, or take the time to develop new techniques." Less than five percent of NIH investigators are selected to receive the MERIT Award, which provides long-term support for researchers, freeing them from the burden of securing and renewing funding for their work year after year. The award has been presented annually since 1987 to individuals whose "paradigm shifting ideas" and "excellent productivity" make them leaders in their field.

Prof. Oren's research gained the attention of the cancer research world in the early 1980s for his role in cloning p53, the "tumor suppressor gene." Since that time, p53 has been the object of intense scientific scrutiny. It soon became clear that p53 is a part of a complex molecular network, that can suppress -- or fail to suppress -- cancerous growth.

The discovery of p53 and its key role in maintaining healthy cells led to a burgeoning new direction in cancer research. Although it is not the only tumor suppressor gene, mutations in the p53 gene are most common in cancer. In normal cells, p53 sets in motion a complex series of molecular events that can cause cell suicide, or apoptosis -- which, despite its name, is a necessary and healthy mechanism that prevents damaged cells from replicating possibly cancerous mistakes in their DNA. When p53 does not function properly, cancerous cells do not undergo apoptosis, and are able to proliferate in the body. Understanding how p53 works, and
'"/>

Contact: Jeffrey J. Sussman
Jeffrey@acwis.org
212-895-7951
American Committee for the Weizmann Institute of Science
11-Nov-2003


Page: 1 2

Related medicine news :

1. Weizmann Institute receives $8 million grant from Flight Attendant Medical Research Institute
2. Weizmann Women & Science Award to be presented to Dr. Carla J. Shatz; Millennial Lifetime Achievement Award to Dr. Mildred S. Dresselhaus
3. Weizmann Institute scientists develop a potential future treatment for myasthenia gravis
4. Gladstone Institutes rank high in the scientist survey of best places for postdocs
5. Institute of Medicine advisory: Jan. 12 Briefing on Complementary and Alternative Medicine
6. Research by scientists affiliated with the Earth Institute at Columbia University
7. New Jersey Institute of Technology pioneers new way to teach engineers
8. Hopkins Institute for Global Tobacco Control receives elite recognition from PAHO/WHO
9. Six new Roybal Centers for Applied Gerontology established by National Institute on Aging
10. American College of Chest Physicians announces new Critical Care Institute
11. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Weizmann Institute Prof Moshe Oren named winner NIH MERIT Award

(Date:3/5/2015)... Southlake, TX (PRWEB) March 05, 2015 ... an in-office, non-surgical treatment for OB-GYNs and Urogynecologists. ... system, used for non-surgical dermatological application in aesthetics ... pleased to have a non-invasive, in-office procedure, and ... for women who want results without surgery. ThermiVa ...
(Date:3/5/2015)... Building on its commitment to provide ... The Academy of Oncology Nurse & Patient Navigators (AONN+) ... voice ™ (CONQUER ™). , “Cancer has ... and their loved ones each year,” says Pam Rattananont ... ever, there is a need in the oncology space ...
(Date:3/4/2015)... MyCpapStore.com, an online provider of CPAP equipment ... quality products designed to remedy the problem of snoring. ... merchandise from name-brand manufacturers, giving its customers access to ... Sleep apnea is a common condition affecting people of ... restricted airflow. The CPAP (continuous positive airway pressure) machine ...
(Date:3/4/2015)... Vegas, NV (PRWEB) March 04, 2015 In ... as the fight that is the main event. For ... and that fight will be for the UFC Featherweight Championship. ... the brash, often out-spoken native of Ireland, Conor “Notorious” McGregor. ... MGM Grand Garden Arena in Las Vegas, NV. , When ...
(Date:3/4/2015)... Dr. Christopher Asandra, M.D., Founder and Chief ... lamented the FDA’s recent decision to issue a ... that FDA’s conclusions are not supported by science, and ... testosterone deficiency. , “The FDA appears to have developed ... said Dr. Asandra. “There is not nearly enough evidence ...
Breaking Medicine News(10 mins):Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 2Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 3Health News:The Academy of Oncology Nurse & Patient Navigators Launches CONQUER: the patient voice™ to Help Meet the Informational Needs of Patients with Cancer 2Health News:Sleep Apnea Machines CPAP and BiPap Machines Now Available for Sale 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... Texas , March 4, 2015 ... II pilot study in patients with moderate to ... Dermatology. The open-label Phase II trial evaluated the ... monoclonal antibody that targets interleukin-1 alpha (IL-1a). IL-1a ... inflammatory cells present in skin lesions. The Company ...
(Date:3/4/2015)... Pa. , March 4, 2015  Results of ... 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin ... poster session at the 32 nd Annual Miami ... study, conducted by Moshe Papa , MD, FACS, ... at Tel Aviv University, reports an analysis of MarginProbe,s ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
Cached News: